Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 627 of 5804
-
New drug combo shows promise for Hard-to-Treat gynecological cancers
Disease control Recruiting nowThe purpose of this research is to test the effectiveness and safety of the study drugs (VS-6766 and defactinib), and see what effects (good and bad) these drugs have on the patients with endometrioid cancer, mucinous ovarian cancer, high-grade serous ovarian cancer, or solid gyn…
Phase: PHASE2 • Sponsor: University of Oklahoma • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Brain-Zap timed to your waves may boost stroke recovery
Symptom relief Recruiting nowWe will investigate the therapeutic efficacy of EEG-synchronized noninvasive repetitive transcranial magnetic stimulation (rTMS) in the early subacute phase after ischemic stroke to improve upper limb motor rehabilitation. We hypothesize that synchronization of rTMS with the phas…
Phase: NA • Sponsor: University Hospital Tuebingen • Aim: Symptom relief
Last updated Jun 27, 2026 12:33 UTC
-
New biologic aims to stabilize platelet counts in ITP patients
Disease control OngoingThe purpose of this study is to evaluate the effect of two different doses of ianalumab versus placebo in addition to first-line corticosteroids in increasing the rate of stable response off treatment at 12 months (SROT-12) in adult participants with primary ITP.
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Radioactive drug takes on standard therapy in lung cancer trial
Disease control Recruiting nowThis phase II trial studies the effect of lutetium Lu 177 dotatate compared to the usual treatment (everolimus) in treating patients with somatostatin receptor positive bronchial neuroendocrine tumors that have spread to other places in the body (advanced). Lutetium Lu 177-dotate…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
Hope for Huntington's: experimental drug targets root cause
Disease control OngoingThis study will evaluate the safety, biomarkers, and efficacy of tominersen compared with placebo in participants with prodromal and early manifest Huntington's Disease (HD).
Phase: PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Gene therapy boost for krabbe patients after transplant
Disease control OngoingThis is a non-blinded, non-randomized dose escalation study of intravenous FBX-101 in which subjects will receive a single infusion of an adeno-associated virus gene therapy product, after more than 21 days of the HSCT (UCBT preferred HSCT source). Data from previously transplant…
Phase: PHASE1, PHASE2 • Sponsor: Forge Biologics, Inc • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
Could a brain pacemaker help stroke survivors move again?
Disease control Recruiting nowThe RESTORE Stroke Study will evaluate the safety and effectiveness of DBS+Rehab for treating arm weakness and reduced function after a stroke.
Phase: NA • Sponsor: Enspire DBS Therapy, Inc. • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Cannabis spray could boost chemo for deadly brain tumors
Disease control Recruiting nowARISTOCRAT is a phase II, multi-centre, double-blind, placebo-controlled, randomised trial to compare the cannabinoid Nabiximols with placebo in patients with recurrent MGMT methylated glioblastoma (GBM) treated with temozolomide (TMZ).
Phase: PHASE2 • Sponsor: University of Birmingham • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Lab-Grown heart cells tested in humans for first time
Disease control Recruiting nowThe goal of this clinical trial is to test the safety of lab-grown heart cells made from stem cells in subjects with congenital heart disease. The main questions it aims to answer are: * Is this product safe to deliver to humans * Is the conduct of this trial feasible Participa…
Phase: PHASE1 • Sponsor: HeartWorks, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
Could a 4-Week drug combo shrink breast tumors before surgery?
Disease control Recruiting nowPREMIERE parallel, non-comparative, two-arm, randomized 1:1, open-label, multicenter, exploratory window of opportunity study in premenopausal women with primary operable HR+/HER2-negative breast cancer with aiming at evaluating the biological effects of elacestrant with or witho…
Phase: PHASE2 • Sponsor: SOLTI Breast Cancer Research Group • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New combo therapy aims to tame melanoma treatment side effects
Disease control Recruiting nowThis study will evaluate how safe the study drug is, how well patients tolerate it, how it works in the body, and the disease's response to the drug. The study drug being tested is sarilumab, when given with the combination of ipilimumab, nivolumab, and relatlimab in patients lik…
Phase: PHASE2 • Sponsor: NYU Langone Health • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
New hope for chronic blood disorder: combo therapy aims to keep platelets stable
Disease control OngoingThe purpose of this study is to evaluate the effect of two different doses of ianalumab added to eltrombopag to prolong Time to Treatment Failure (TTF) in adults with primary ITP who failed previous first-line treatment with steroids.
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug cocktail aims to stall Hard-to-Treat prostate cancer
Disease control OngoingThis is a multicenter, single-arm, two-stage open-label phase 2 study of the combination of cabozantinib + nivolumab in subjects with advanced castration-resistant prostate cancer (CRPC).
Phase: PHASE2 • Sponsor: Rana McKay, MD • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
New hope for tough ovarian cancer: targeted drug shows promise in trial
Disease control CompletedThe purpose of the study is to assess the safety, tolerability, and efficacy of farletuzumab ecteribulin (MORAb-202) and compare it to Investigator's choice (IC) chemotherapy in female participants with platinum-resistant HGS ovarian, primary peritoneal, or fallopian tube cancer.
Phase: PHASE2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
Radiation boost may tame untreatable kidney cancer
Disease control Recruiting nowThis phase II trial tests whether the addition of radiation to the primary tumor, typically given with stereotactic ablative radiation therapy (SABR), in combination with standard of care immunotherapy improves outcomes in patients with renal cell cancer that is not recommended f…
Phase: PHASE2 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Family history lung cancer screening study launches in hong kong
Knowledge-focused Recruiting nowLung cancer can be detected via screening of high-risk individuals, i.e current or ex-heavy smokers, with low-dose computer tomography (LDCT) of thorax. The National Lung Screening Trial in US and the NELSON trial in Europe demonstrated reduction in lung cancer mortality with LDC…
Sponsor: The University of Hong Kong • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:05 UTC
-
New hope for kids with rare immune disease: drug targets root cause
Disease control OngoingThis is a 2-part, prospective, open-label, single arm, multicenter study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and efficacy of leniolisib in at least 15 pediatric patients (aged 4 to 11 years) with activated phosphoinositide 3-kinase…
Phase: PHASE3 • Sponsor: Pharming Technologies B.V. • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Can housing and counseling curb gun violence? new haven study aims to find out
Prevention Recruiting nowThe overall objective of this study is to implement and test a strengths-based, community-driven intervention to reduce gun violence by (1) improving housing stability through providing financial assistance coupled with comprehensive financial education for the re-entry populatio…
Phase: NA • Sponsor: Yale University • Aim: Prevention
Last updated Jun 27, 2026 09:04 UTC
-
New hope for rare gut cancers: triple-drug combo shows promise
Disease control Recruiting nowTo explore the safety and efficacy of Surufatinib and Sintilimab in Combination With Capecitabine in Patients With Previously Treated Metastatic Adenocarcinoma of Small Intestine or Appendix Carcinoma : a Single-arm, a Single-center , Phase 2 Trial. Meanwhile, Exploring the maxim…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
New combo aims to wipe out prostate tumors before surgery
Disease control OngoingPhase 2 open-label, single-arm clinical trial evaluating the efficacy and safety of neoadjuvant olaparib + LHRH agonist administered for 6 months prior to radical prostatectomy (RP) in men with unfavorable intermediate-risk or high-risk localized prostate cancer. All patients mus…
Phase: PHASE2 • Sponsor: Rana McKay, MD • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC